clement, Author at BaseLaunch

Features

Plug & Play Lab Space for R&D at Switzerland Innovation Park Basel Area

Switzerland Innovation Park Basel Area offers fully equipped plug & play labs for early stage life sciences projects and startups, ideal for aspiring founders.

clement03.07.2018

Features

NBE Therapeutics secures new investor

Danish investor Novo Holdings is investing 20 million Swiss francs in NBE Therapeutics in a series B financing round. The Basel-based biotechnology company develops novel…

clement02.07.2018

Features

Where the life sciences are concentrated

As one of the world’s leading locations for life sciences, the Basel region is home to a cluster of companies and organizations that not only…

clement26.06.2018

Features

A quest to drug the undruggable

Undruggable - The latest Stereo Chemistry episode explores why certain drug targets are so vexing, and the cutting edge approaches chemists are taking to finally…

clement22.06.2018

Human immune cells can eliminate cancer cells. Anaveon has developed a special antibody to boost the body’s own defense mechanism. The picture shows an electron-microscopic view of one of the immune system’s CD8 killer cells. (Image: NIAID/flickr)

Portfolio news

BaseLaunch backed Anaveon received funding

Onur Boyman, an immunologist working at the University Hospital Zurich and UZH, has joined forces with Andreas Katopodis to establish Anaveon, a BaseLaunch participant. Aiming to translate…

clement20.06.2018

Features

Roche bags full control of Foundation Medicine in $2.4B follow-up buyout

clement19.06.2018

Interviews

“Basel has all the ingredients required to host a successful company”

The physician and pharmacologist Nicole Onetto is a member of the Board of Directors at the Basilea Pharmaceutica AG. In the Interview that was featured…

clement11.06.2018

Interviews

Processes kill innovation

The serial entrepreneur Neil Goldsmith is drawn to new ventures. Annett Altvater from BaselArea.swiss talked to him about how to detect startup-suitable talent and his…

clement07.06.2018

Features

Does Theranos mark the peak of the Silicon Valley bubble?

John Carreyrou talks to Nautilus about the lessons of a $1 billion fraud. BY MICHAEL SEGALMAY 31, 2018 Silicon Valley has a term for startups…

clement31.05.2018

Features

From Rock DJ to Scientist to Entrepreneur: Michael Gilman on The Long Run Podcast

Currently (2018) Michael Gilman is the CEO of two biotech startups – Arrakis Therapeutics, a company attempting to make small molecule drugs against RNA targets;…

clement30.05.2018

clement

Plug & Play Lab Space for R&D at Switzerland Innovation Park Basel Area

NBE Therapeutics secures new investor

Where the life sciences are concentrated

A quest to drug the undruggable

BaseLaunch backed Anaveon received funding

Roche bags full control of Foundation Medicine in $2.4B follow-up buyout

“Basel has all the ingredients required to host a successful company”

Processes kill innovation

Does Theranos mark the peak of the Silicon Valley bubble?

From Rock DJ to Scientist to Entrepreneur: Michael Gilman on The Long Run Podcast

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us